Local med-tech company, Bedfont® Scientific Ltd., is recognised for its Innovation for the 2ndyear in a row at the Kent Invicta Chamber of Commerce (KICC) Awards

On Thursday 17th November 2022, Kent’s esteemed businesses gathered at Westenhanger Castle for the annual Kent Invicta Chamber of Commerce (KICC) Awards to celebrate the achievements of Kent companies. Bedfont is delighted to share that it has been named as Innovative Business of the Year, for the 2nd year running.

Bedfont, who design and manufacture breath analysis medical devices, have been trading since 1976, and export their products across the globe thanks to their network of carefully selected distributors.

Amidst the challenges posed by COVID, Bedfont® used its innovative nature to adapt its products and services to successfully navigate the pandemic, and as a result has come out the other side stronger, now offering remote breath testing devices.

Jason Smith, Managing Director at Bedfont, explains, “We created webinars and marketing materials to educate our customers on how they could safely continue breath testing. This led to a Healthcare Professional contacting us, asking for a way to help them continue CO monitoring for smoking cessation remotely. The iCOquit® was designed as a personal CO monitor, however we adapted this and the accompanying app and literature to enable the iCOquit® to be used for remote CO testing. This was so successful, the market then asked for a version to help expectant mothers quit smoking, and we provided –these innovative moves helped us succeed during a time of economic regression The Bedfont Family worked so hard to make this happen and I couldn’t be prouder to share this Innovation award with them.”

Kent Family Business, Bedfont® Scientific Ltd., have been awarded Bronze, Silver, and Gold Kent and Medway Healthy Workplace Awards.

In 2022, Bedfont® joined the Healthy Workplace Programme, which involves building new initiatives and putting the wellbeing of employees at the forefront of the business. Bedfont is pleased to announce it has received 3 awards for their efforts to create a positive workplace environment.

The programme funded by the KCC and Medway Council, helps to support health and wellbeing at work with relevant policies, training and guidance(1). Recent studies have shown that those with a healthy work/life balance have more motivation and are more productive at work(2).

Jason Smith, Managing Director at Bedfont®, comments, “As a second-generation family business, Bedfont® has implemented workplace policies that focus on creating a friendly and positive workplace atmosphere with the Bedfont Family at its heart. We have been working hard to achieve a healthy work/life balance for our employees for some time now, and it’s really rewarding for us as an employer to know this has been recognised with the Healthy Workplace Awards. We look forward to continuing and improving upon these efforts, and we have our sights set on the Platinum award next.”

The Kent and Medway awards team, comments, “From the great evidence submitted and interviews conducted, it is evident Bedfont Scientific has created a very social and inclusive organisation which always looks at ways to introduce new initiatives and equally cares for the wellbeing of its customers as much as its staff. Well done to you and all your hard work in making Bedfont Scientific a lovely place to work”

References:

  1. Council M. Kent and Medway Healthy Workplace Programme | Medway Council [Internet]. Medway.gov.uk. 2022 [cited 6 October 2022]. Available from: https://www.medway.gov.uk/healthyworkplace
  2. 10 Statistics on Work-Life Balance That May Surprise You (2022) [Internet]. Apollo Technical LLC. 2022 [cited 23 September 2022]. Available from: https://www.apollotechnical.com/statistics-on-work-life-balance/

Bedfont’s NObreath® monitor for airway inflammation has been cleared for sale in the USA

UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.

The NObreath®, which conforms to ATS and ERS guidelines1, is a portable, non-invasive device for the measurement of Fractional Exhaled Nitric Oxide (FeNO) in human breath. The production of nitric oxide is often found to be increased in inflammatory conditions such as asthma.

The NObreath® works by measuring FeNO through breath analysis, making the process quick, simple, and non-invasive for both the Healthcare Professional and the patient. Interpreting FeNO levels aids in identifying patients who do/do not require ongoing treatment2 whilst also differentiating between allergic (eosinophilic) and non-allergic asthma3, and if used daily, FeNO measurements can help to predict and prevent exacerbations and attacks4.

Jason Smith, Managing Director at Bedfont, comments, “NObreath has been available outside the US for over 12 years now, we have been working towards FDA clearance for quite some time and we are over the moon to have received it. We are one step closer to achieving our purpose; to make FeNO monitoring lower cost and therefore more accessible globally. According to the Centre for Disease Control (CDC), around 25 million Americans suffer from asthma; that’s a potential 25 million people that the NObreath® can help through FeNO monitoring.”

-ends-

REFERENCES

  1. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005; American Journal of Respiratory and Critical Care Medicine; vol. 171: 912-930;2005
  2. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
  3. Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 21 December 2021]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
  4. Harkins M. Exhaled Nitric Oxide Predicts Asthma Exacerbation [Internet]. Taylor & Francis. 2017 [cited 21 December 2021]. Available from: http://www.tandfonline.com/doi/abs/10.1081/JAS-120033990

Bedfont and its sponsored football team, Medway United FC, have teamed up to donate 125 gifts to Medway hospital and 125 gifts to Children’s Cancer Charity, My Shining Star

Medical device manufacturer, Bedfont Scientific Ltd., has joined forces with the local football team it sponsors, Medway United FC, to spread a little Christmas Joy by donating 250 gifts. On Tuesday 14th December, Bedfont and Medway United donated 125 gifts to Medway Hospital for the children who will be there over Christmas, and another 125 gifts to the children’s cancer charity ‘My Shining Star’ also based in Medway.

Jason Smith, Managing Director at Bedfont, “Winston Churchill said, ‘We make a living by what we get. We make a life by what we give.’ Medway United and Bedfont are happy to spread some festive cheer at a time of year, which can be so difficult for many.”

Cherly Jones, Fundraising Officer at the Medway Hospital Charity, “We are extremely grateful to Bedfont and Medway United for their incredible donation of presents to our children’s ward at Medway Hospital.  Their generosity is very much appreciated, especially at this time of year, and I know our patients will be thrilled to receive them.”

Local medical device manufacturer, Bedfont Scientific Ltd., returns to the era it all began for its 45th birthday

On 8th December, Kent Med-tech company, Bedfont Scientific Ltd. celebrated 45 years of business with a 1970’s themed party. The Bedfont Family celebrated with costumes from prominent 70’s characters, 70’s party games, 70’s party food, and a video tribute from a number of employees and distributors who have contributed to the business since 1976.

Jason Smith, Managing Director, remarks, “Back in 1976 the incidence of serious hazards related to medical gas supply systems was described as ‘alarming’. My favourite inspirational quote is ‘a pessimist sees the difficulty in every opportunity, an optimist sees the opportunity in every difficulty’ from Winston Churchill. I think this describes very aptly how my godfather, John Marron, went on to design and manufacture Bedfont’s first ever product; the TM3 Medi-Gas Check for ensuring gas supply systems were safe before use. This product undoubtedly saved lives and started Bedfont on a road of life-saving gas monitors. Back then, Bedfont employed one person and was based in a bedsit in London; now we employ 50 direct staff, have over 80 global distributors, and even have our own offices in Kent and Austria. We will continue to innovate new non-invasive breath analysis devices to bring these life-saving products into people’s homes worldwide, and hope to do so for the next 45 years!”

The KICC awards recognises Med-tech company, Bedfont’s innovative success

The long-awaited Kent Invicta Chamber of Commerce (KICC) awards took place on Thursday 18th November, and named medical device manufacturer, Bedfont, as Innovative Business of the Year.

The KICC awards, celebrated every year, brings together businesses across Kent, showcasing their amazing achievements. The awards had unfortunately been delayed due to COVID-19, but finally took place on Thursday at Westhanger Castle, Hythe, boasting an even more impressive evening than ever before.

Local medical technology business, Bedfont, was delighted to have received the accolade for Innovative business of the year. A multi-award winning medical device manufacturer, Bedfont is based in Harrietsham, Kent. Their products help to detect a range of medical conditions via breath analysis, removing the need for needles, blood samples, and long waiting time for results.

Managing Director, Jason Smith, explained, “It’s been a difficult couple of years, being a breath analysis device manufacturer during the Coronavirus pandemic – a disease spread by breath! However, Bedfont did what it does best; innovate. We adapted our products, resources, and services to better support both our employees and customers remotely and the Bedfont Family are over the moon to see that this has been recognised.”

Medical device manufacturer, Bedfont, signs an ODM deal to supply Kangdu with its NObreath FeNO monitor

Shenzhen Century Kangdu Medical Technology Co., Ltd. was established in 2017. The company is located in Pingshan District, Shenzhen, focusing on the R&D, manufacturing and sales of respiratory testing medical devices. Kangdu has signed an Original Design Manufacturer (ODM) agreement with Bedfont for the new NObreath Fractional exhaled Nitric Oxide (FeNO) monitor.

FeNO is a biomarker for airway inflammation, helping in the control and diagnosis of asthma and also the differentiation between asthma and other respiratory diseases.  Measuring FeNO through breath analysis, making the process quick, simple and non-invasive for both the GP and the patient. Interpreting FeNO levels aids in identifying patients who do/do not require on-going treatment whilst also differentiating between allergic (eosinophilic) and non-allergic asthma, and if used daily, FeNO measurements can help to predict exacerbations and attacks.

The ODM agreement for NObreath means Bedfont designs and manufactures the monitor and Kangdu distributes the product under their branding, EZbreath.

Mr. Zhu Chun Ming, Managing Director at Kangu, commented, “Bedfont’s NObreath is a very innovative and patient-friendly device; we are excited to integrate this monitor into our existing range of high-quality respiratory medical devices and help Bedfont expand its reach through the medical market in China.”

Jason Smith, Managing Director at Bedfont, adds, “We are looking forward to working with Kangdu to help improve asthma diagnosis and management in China. This new strategic partnership is a huge step for Bedfont as it will enable us to access this new market and help us to further highlight FeNO breath testing and its benefits.”

Since 2019, COVID-19 has become a significant part of our lives. As we try to adjust to our new way of life, our knowledge surrounding covid-19 and how we must adapt and innovate as a company significantly grows. Science is amazing! and the fact that we have access to so many resources and tools helping us understand and develop solutions to beat this virus just goes to show how far we have come as a society with technology, however sometimes we can become overwhelmed with the sheer volume of information around the COVID-19 topic, and it can become hard to digest, especially when we hear about new scary variants of COVID-19 rampant throughout our communities. Therefore we aim to settle your fears and concerns surrounding the COVID-19 delta variant, and the steps our company has taken to protect and reduce this new risk to you, so you can continue to use your monitors to provide that much needed support to your patients.

The virus, COVID-19, belongs to the Coronaviridae family, their shape is typically spherical with crown-like spikes on the outer surface1. This family of viruses are generally 125nm in diameter, but can be as small as 65nm1.  Viruses are renowned for mutating quickly3, in fact COVID-19 is described as having a relatively sluggish mutation rate in comparison to other established viruses2, however researchers have catalogued more than 12,000 mutations since the start of the pandemic2.

It is important to note a great majority of these mutations will have no consequence to the viruses’ ability to spread or cause disease2.  Some variants will however be significant, with the variant of concern being the COVID-19 Delta variant, warned by scientists over the world to be considerably more transmissible and contagious than other COVID variants.

The delta variant has a combination of (not limited to) two key mutations;

  1. A mutation at location 452 of the spike protein allows this particular variant of COVID-19 to bind more effectively to the ACE2 receptor protein, a protein found on the surface of the lung, meaning the virus can invade cells more effectively in comparison to other COVID-19 variants4.
  2. Mutation at position 478 on delta variant spikes which enables the virus to evade weak neutralising anti-bodies4.

The combination of the above mutations coupled with original mutations from the original virus makes for the delta variant to become a variant of considerable concern globally. However, Bedfont® Scientific has independently tested our mouthpiece filters to filter viruses as small as 24 nanometres5. In comparison, the model virus used to filter viruses are significantly smaller than the approximate size of viruses from the Coronaviridae family. The virus model used to test Bedfont®’s mouthpiece filters are incredibly penetrable, even more so than a majority of human viruses, therefore makes it a very effective model to use for virus filtration efficiency (VFE) testing.

In conclusion, Bedfont® can deduce that there is no current evidence to suggest the delta variants approximate size has significantly changed or is a significantly different size in other COVID variants of concern, and therefore the testing conducted on our mouthpiece filters is still effective. We maintain that bacterial and viral pathogens (including Delta variant COVID-19) will effectively be removed by both the D-piece™ and OneBreath™ mouthpiece filter at an efficiency rate of >99% (bacteria) and >97% (viruses), and >99% (bacteria) and >98% (viruses) for the Second Generation NObreath® mouthpiece filter.  

References:

  1. Shereen M, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020;24:91-98.
  2.  Callaway E. The coronavirus is mutating — does it matter? [Internet]. Nature.com. 2021 [cited 14 July 2021]. Available from: https://www.nature.com/articles/d41586-020-02544-6
  3. Grubaugh N, Petrone M, Holmes E. We shouldn’t worry when a virus mutates during disease outbreaks. 2021.
  4. Mishra S. The Delta variant is spreading fast, especially where vaccination rates are low [Internet]. Science. 2021 [cited 14 July 2021]. Available from: https://www.nationalgeographic.com/science/article/the-delta-variant-is-serious-heres-why-its-on-the-rise
  5. Berkeywaterkb.com. 2020. Is The MS2 – Fr Coliphage Still Known To Be A Good Indicator Of Virus Filtration? Do You Have Tests On Any Other Viruses? – Berkey Knowledge Base. [online] Available at: http://berkeywaterkb.com/is-the-ms2-fr-coliphage-still-known-to-be-a-good-indicator-of-virus-filtration-at-least-one-article-suggests-that-it-might-not-be-do-you-have-tests-on-any-other-viruses/#:~:text=The MS-2 virus is 24-26,both referenced on the chart [Accessed 12 June 2020].
  1.  Grubaugh N, Petrone M, Holmes E. We shouldn’t worry when a virus mutates during disease outbreaks. 2021.
  2. Mishra S. The Delta variant is spreading fast, especially where vaccination rates are low [Internet]. Science. 2021 [cited 14 July 2021]. Available from: https://www.nationalgeographic.com/science/article/the-delta-variant-is-serious-heres-why-its-on-the-rise
  3. Berkeywaterkb.com. 2020. Is The MS2 – Fr Coliphage Still Known To Be A Good Indicator Of Virus Filtration? Do You Have Tests On Any Other Viruses? – Berkey Knowledge Base. [online] Available at: http://berkeywaterkb.com/is-the-ms2-fr-coliphage-still-known-to-be-a-good-indicator-of-virus-filtration-at-least-one-article-suggests-that-it-might-not-be-do-you-have-tests-on-any-other-viruses/#:~:text=The MS-2 virus is 24-26,both referenced on the chart [Accessed 12 June 2020].

Bedfont has seen a high demand for its NObreath® FeNO monitor following Rapid Uptake Products(RUP) programme

Med-tech company, Bedfont, has seen a rise in demand for its NObreath® FeNO monitor, which aids in the diagnosis and monitoring of asthma, since the airway inflammation measurement tool was included on the Rapid Uptake Products (RUPs) programme.

The RUPs programme designed by the NHS Accelerated Access Collaborative (AAC), identifies products with NICE approval, such asFeNO testing devices, and supports them by helping these innovative products integrate into everyday practice. Thanks to the RUPs programme, NHS organisations were able to apply for funding through the government ‘Pathway Transformation Funding’ (PTF) initiative which helps to cover the costs of devices, consumables and fund other infrastructure requirements to set up FeNO testing (among other services) as part of the patient care pathway.

Jason Smith, Managing Director of Bedfont, said, “Since NICE published guidance relating to FeNO testing some years ago, it has been disheartening to see how many services want to integrate this approved technology into their services but have been unable due to lack of funding and/or education surrounding its use. The AAC have created a platform by which services have been able to secure the vital funding twinned with educational tools.Since applications closed on 30th April 2021, we have seen a high rise in the demand for our FeNO monitors and we are ecstatic to be helping to improve asthma care.”

Bedfont has been fighting to get FeNO monitoring widely accepted worldwide, by raising awareness of measuring FeNO and its benefits for asthma by providing online resources, expert-lead seminars, and a no-nonsense pricing structure.

In collaboration with their UK distributor, Intermedical UK Ltd, Bedfont will provide many devices as part of the programme but are aware that only a small percentage of applications will be successful. For any services that have not been fortunate to secure funding for a NObreath® FeNO device, Intermedical has a limited offer available. Please contact Intermedical on 01732 522444to solve your FeNO monitoring needs today.

Local company, Bedfont Scientific Ltd., fundraises and skydives to raise money for the Heart of Kent Hospice

On Sunday 13th June, a group of Bedfont employees daringly jumped from a plane in a bid to raise £3000 for local charity, Heart of Kent Hospice, who provides specialist palliative care, advice and clinical support for adults with life limiting illness and their families in Kent.

Each member of the Bedfont Family had their own personal reasons for supporting the charity and the Skydive was a new and brilliant adventure for them to undertake.

Jason Smith, Managing Director at Bedfont, commented, “We’re incredibly proud of Katie, Amber, Amy, Ryan, Hannah, and Tom for taking on this challenge to fundraise for a great charity, and we’re very grateful to all our friends, family, co-workers and business partners who have donated to such a great cause. We’re still a few pounds away our fundraising goal of £3000 so if you would like to donate to a good cause, please visit our Just Giving page.”

To donate to the Heart of Kent Hospice, please visit: https://www.justgiving.com/fundraising/bedfont-scientific